{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:03:01Z","timestamp":1792011781473,"version":"4.4.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81774084 81804020"],"award-info":[{"award-number":["81774084 81804020"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Berberine is a natural plant alkaloid isolated from a diverse range of genera, it obtains anti-inflammatory, anti-obesity, and hepatoprotective properties, and is a promising agent for non-alcoholic steatohepatitis (NASH). Farnesoid X receptor (FXR) is a bile acid receptor and a drug target for NASH, however, the underlying mechanisms of berberine on regulating FXR are still unknown. In the present study, we feed mice with a 12-week high-fat diet with interval dextran sulfate sodium (0.5% in drinking water) diet to induce NASH, and treat the mice with berberine (100\u00a0mg\/kg per day) <jats:italic>via<\/jats:italic> oral gavage for additional 4\u00a0weeks. We demonstrate that administration of berberine alleviates steatosis and infiltration of inflammatory cells in the liver of NASH mice. We apply 16S ribosomal DNA sequencing to screen the structure of gut microbiota, and ultra-performance liquid chromatography-tandem mass spectrometry analysis to determine the bile acid profiles. The results show that berberine modulates gut dysbiosis, and specifically increases the relative abundance of <jats:italic>Clostridiales<\/jats:italic>, <jats:italic>Lactobacillaceae,<\/jats:italic> and <jats:italic>Bacteroidale<\/jats:italic>. Berberine modulated microbiomes are associated with bile acid de-conjugation and transformation, which are consistent with the altered bile acid species (e.g., deoxycholic acid, ursodeoxycholic acid) upon berberine treatment. BA species that respond to berberine treatment are known FXR agonists, thus we performed quantitative Real Time-PCR and western blot to examine the FXR pathway, and find that berberine up-regulates intestinal FXR and fibroblast growth factor 15 (FGF15) expression, and the secretion of FGF15 further inhibits lipogenesis and nuclear factor-\u03baB activation in the liver. Whereas the beneficial effects of berberine are blunted in FXR knockout mice. Our results reveal that berberine alleviates NASH by modulating the interplay of gut microbiota and bile acid metabolism, as well as the subsequent intestinal FXR activation.<\/jats:p>","DOI":"10.3389\/fphar.2021.750826","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T04:23:59Z","timestamp":1631852639000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":56,"title":["Berberine Alleviates Non-alcoholic Steatohepatitis Through Modulating Gut Microbiota Mediated Intestinal FXR Activation"],"prefix":"10.3389","volume":"12","author":[{"given":"Xiangbing","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.bbrc.2015.12.012","article-title":"DSS Colitis Promotes Tumorigenesis and Fibrogenesis in a Choline-Deficient High-Fat Diet-Induced NASH Mouse Model","volume":"470","author":"Achiwa","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The Natural History of Nonalcoholic Fatty Liver Disease: a Population-Based Cohort Study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fphar.2020.00041","article-title":"Phytopharmacology and Clinical Updates of Berberis Species against Diabetes and Other Metabolic Diseases","volume":"11","author":"Belwal","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long-term Follow-Up of Patients with NAFLD and Elevated Liver Enzymes","volume":"44","author":"Ekstedt","year":"2006","journal-title":"Hepatology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1021\/acs.molpharmaceut.6b01155","article-title":"Impact of Gut Microbiota-Mediated Bile Acid Metabolism on the Solubilization Capacity of Bile Salt Micelles and Drug Solubility","volume":"14","author":"Enright","year":"2017","journal-title":"Mol. Pharm."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.jhep.2011.02.035","article-title":"DSS Induced Colitis Increases portal LPS Levels and Enhances Hepatic Inflammation and Fibrogenesis in Experimental NASH","volume":"55","author":"G\u00e4bele","year":"2011","journal-title":"J. Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1053\/j.gastro.2016.08.057","article-title":"An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease","volume":"151","author":"Gonzalez","year":"2016","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1021\/acs.jproteome.8b00945","article-title":"Metabolic and Gut Microbial Characterization of Obesity-Prone Mice under a High-FaDiet","volume":"18","author":"Gu","year":"2019","journal-title":"J. Proteome Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1038\/s41467-019-09852-0","article-title":"Liver-target Nanotechnology Facilitates Berberine to Ameliorate Cardio-Metabolic Diseases","volume":"10","author":"Guo","year":"2019","journal-title":"Nat. Commun."},{"key":"B10","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/s12906-016-1367-7","article-title":"Dose-response Effect of Berberine on Bile Acid Profile and Gut Microbiota in Mice","volume":"16","author":"Guo","year":"2016","journal-title":"BMC Complement. Altern. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for Treatment of Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/978-981-10-8684-7_8","article-title":"The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease","volume":"1061","author":"Jia","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"10166","DOI":"10.1038\/ncomms10166","article-title":"Intestine-selective Farnesoid X Receptor Inhibition Improves Obesity-Related Metabolic Dysfunction","volume":"6","author":"Jiang","year":"2015","journal-title":"Nat. Commun."},{"key":"B13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/hep.27677","article-title":"Farnesoid X Receptor-Induced Lysine-specific Histone Demethylase Reduces Hepatic Bile Acid Levels and Protects the Liver against Bile Acid Toxicity","volume":"62","author":"Kim","year":"2015","journal-title":"Hepatology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jep.2014.09.049","article-title":"Meta-analysis of the Effect and Safety of Berberine in the Treatment of Type 2 Diabetes Mellitus, Hyperlipemia and Hypertension","volume":"161","author":"Lan","year":"2015","journal-title":"J. Ethnopharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1038\/ncomms3384","article-title":"Microbiome Remodelling Leads to Inhibition of Intestinal Farnesoid X Receptor Signalling and Decreased Obesity","volume":"4","author":"Li","year":"2013","journal-title":"Nat. Commun."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1002\/ptr.7055","article-title":"Isotschimgine Alleviates Nonalcoholic Steatohepatitis and Fibrosis via FXR Agonism in Mice","volume":"35","author":"Li","year":"2021","journal-title":"Phytother Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"12748","DOI":"10.1021\/acs.jmedchem.0c01065","article-title":"Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis","volume":"63","author":"Li","year":"","journal-title":"J. Med. Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"112896","DOI":"10.1016\/j.jep.2020.112896","article-title":"Qiang-Gan Formula Extract Improves Non-alcoholic Steatohepatitis via Regulating Bile Acid Metabolism and Gut Microbiota in Mice","volume":"258","author":"Li","year":"","journal-title":"J. Ethnopharmacol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.taap.2016.10.011","article-title":"UDCA and CDCA Alleviate 17\u03b1-Ethinylestradiol-Induced Cholestasis through PKA-AMPK Pathways in Rats","volume":"311","author":"Li","year":"2016","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"dgaa382","DOI":"10.1210\/clinem\/dgaa382","article-title":"Effect of Gut Microbiota and PNPLA3 Rs738409 Variant on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Youth","volume":"105","author":"Monga Kravetz","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B21","doi-asserted-by":"publisher","first-page":"101113","DOI":"10.1016\/j.molmet.2020.101113","article-title":"FGF15\/19 Is Required for Adipose Tissue Plasticity in Response to Thermogenic Adaptations","volume":"43","author":"Mor\u00f3n-Ros","year":"2021","journal-title":"Mol. Metab."},{"key":"B22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3389\/fphar.2018.00557","article-title":"Berberine: Botanical Occurrence, Traditional Uses, Extraction Methods, and Relevance in Cardiovascular, Metabolic, Hepatic, and Renal Disorders","volume":"9","author":"Neag","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1007\/s10620-016-4179-1","article-title":"Impact of Hypocaloric Hyperproteic Diet on Gut Microbiota in Overweight or Obese Patients with Nonalcoholic Fatty Liver Disease: A Pilot Study","volume":"61","author":"Pataky","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"7703","DOI":"10.1021\/acs.jmedchem.7b00398","article-title":"A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase to Counter Nonalcoholic Steatohepatitis","volume":"60","author":"Schmidt","year":"2017","journal-title":"J. Med. Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1124\/mol.116.106617","article-title":"Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway","volume":"91","author":"Sun","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e00131","DOI":"10.14309\/ctg.0000000000000131","article-title":"Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC","volume":"11","author":"Sydor","year":"2020","journal-title":"Clin. Transl. Gastroenterol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"7352","DOI":"10.3390\/ijms15057352","article-title":"Molecular Mechanisms and New Treatment Strategies for Non-alcoholic Steatohepatitis (NASH)","volume":"15","author":"Takaki","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1124\/dmd.118.083691","article-title":"Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation","volume":"47","author":"Tian","year":"2019","journal-title":"Drug Metab. Dispos"},{"key":"B38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3389\/fmed.2017.00163","article-title":"Interactions between Bacteria and Bile Salts in the Gastrointestinal and Hepatobiliary Tracts","volume":"4","author":"Urdaneta","year":"2017","journal-title":"Front. Med. (Lausanne)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1039\/c8fo02181c","article-title":"Cholesterol-lowering Potentials of Lactobacillus Strain Overexpression of Bile Salt Hydrolase on High Cholesterol Diet-Induced Hypercholesterolemic Mice","volume":"10","author":"Wang","year":"2019","journal-title":"Food Funct."},{"key":"B29","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41419-019-1706-y","article-title":"Berberine Promotes the Recruitment and Activation of Brown Adipose Tissue in Mice and Humans","volume":"10","author":"Wu","year":"2019","journal-title":"Cell Death Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e0134172","DOI":"10.1371\/journal.pone.0134172","article-title":"Efficacy of Berberine in Patients with Non-alcoholic Fatty Liver Disease","volume":"10","author":"Yan","year":"2015","journal-title":"PLoS One"},{"key":"B31","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.metabol.2008.01.013","article-title":"Efficacy of Berberine in Patients with Type 2 Diabetes Mellitus","volume":"57","author":"Yin","year":"2008","journal-title":"Metabolism"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1365-2036.2008.03710.x","article-title":"Review Article: Current Management of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis","volume":"28","author":"Younossi","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"166153","DOI":"10.1016\/j.bbadis.2021.166153","article-title":"Secondary (iso)BAs Cooperate with Endogenous Ligands to Activate FXR under Physiological and Pathological Conditions","volume":"1867","author":"Zaufel","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1038\/s41467-020-18414-8","article-title":"Gut Microbiome-Related Effects of Berberine and Probiotics on Type 2 Diabetes (The PREMOTE Study)","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat. Commun."},{"key":"B35","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1186\/s12864-019-6251-7","article-title":"Changes of Intestinal Bacterial Microbiota in Coronary Heart Disease Complicated with Nonalcoholic Fatty Liver Disease","volume":"20","author":"Zhang","year":"2019","journal-title":"BMC Genomics"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/hep.30702","article-title":"Unexpected Rapid Increase in the Burden of NAFLD in China from 2008 to 2018: A Systematic Review and Meta-Analysis","volume":"70","author":"Zhou","year":"2019","journal-title":"Hepatology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.750826\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T04:24:02Z","timestamp":1631852642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.750826\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":39,"alternative-id":["10.3389\/fphar.2021.750826"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.750826","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,17]]},"article-number":"750826"}}